Vedanta Biosciences said it significantly reduced headcount and refocused resources on advancing VE303, an eight‑strain live bacterial consortium aimed at preventing recurrent Clostridioides difficile infection. The company cited the need to concentrate funds on its phase 3 VE303 program and has targeted trial completion dates consistent with a mid‑2027 timetable. Management framed the moves as prioritization rather than shutdown of core efforts. The restructuring follows prior program stoppages and mirrors a broader funding pressure for microbiome therapeutics after mixed clinical results across the field. Vedanta’s reallocation underscores the high cost of late‑stage microbiome development and the narrow runway for companies to reach registrational success absent new financing or partnerships.